Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook
On December 1, 2025, Q32 Bio Inc. suddenly became one of the most-watched small-cap biotech stocks on Wall Street. Shares of Q32 Bio surged intraday by roughly 90%–170% at various points in Monday’s session, with trading volume soaring from a typical few hundred thousand shares to tens or even hundreds of millions, after the company announced a major asset sale to Akebia Therapeutics. TipRanks+224/7 MarketNews+2 At the center of the move: the sale of Q32 Bio’s Phase 2 complement inhibitor ADX-097 to Akebia in a deal worth $12 million in upfront and near-term cash and up to $592 million in potential milestones, plus future royalties – and a strategic refocus on the company’s lead autoimmune drug, bempikibart, for alopecia areata. citybiz+2StreetInsider.com+2
